New Form of Aminazine® Is Already on Sale

New Form of Aminazine® Is Already on Sale

17.08.2015

Valenta informs about introduction to the Russian market of a new medicinal form of Aminazine® neuroleptic (with chlorpromazine as the agent). Now the medicine is available in the form of film-coated tablets in doses of 25 mg, 50 mg and 100 mg. There is a distinctive feature of the tablet form of Aminazine® — tablets differ by colors depending on the dosage. Thus, tablets of 25 mg are white-yellow, 50 mg — brown-pink, 100 mg — red-brown; so the intuitively understandable color marking of the medicine simplifies its use by the patient, especially at prescription of «intermediate» dozes. The company’s initiative is aimed to increase therapy compliance at treatment with different dosages of Aminazine®.

Aminazine® is one of the most often prescribed neuroleptics in Russia; this medicine is well-known among both medical community and drugstore staff. The experience of the medicine active application is the evidence of its high demand on the pharmaceutical market.

Andrei Agafonov, Head of the Directorate for Psychoneurological Portfolio Promotion, OAO «Valenta Pharm»: «Production of Aminazine® new form in Russia is Valenta’s next step in its development — it confirms the company’s commitment to follow the advanced global trends. Unlike in Europe and the USA, where chlorpromazine is produced in tablets, this medicinal form was not available on the Russian pharmaceutical market before 2015.»

About Aminazine®

Aminazine® is a typical neuroleptic actively applied in psychiatry. Aminazine is included into the EML and many therapeutic standards, such as: the standard of special medical assistance at psychotic disorders caused by psychoactive substances misuse; the standard of special medical assistance at dependency syndrome caused by psychoactive substances misuse; the standard of special medical assistance at specific personality disorders; the standard of emergency medical assistance at schizophrenia, schizotypal or delusional disorders; the standard of primary medical and sanitary assistance at personality and behavioral disorders in adults, in out-patient conditions of a psychoneurological clinic (out-patient department, out-patient unit); the standard of primary medical and sanitary assistance at organic, including symptomatic, mental disorders and dementia in out-patient conditions of a psychoneurological clinic (out-patient department, out-patient unit); the standard of emergency medical assistance at organic, symptomatic mental disorders; the standard of special medical assistance at schizophrenia, in acute (subacute), long-lasting phase and prevalence of socio-rehabilitation problems; the standard of special medical assistance at schizophrenia in subacute phase, in conditions of daycare facilities; the standard of primary medical and sanitary assistance at organic, including symptomatic, mental disorders, psychoses associated with epilepsy, in out-patient conditions of a psychoneurological clinic (out-patient department, out-patient unit); the standard of primary medical and sanitary assistance at organic, including symptomatic, mental disorders, dementia associated with epilepsy, in out-patient conditions of a psychoneurological clinic (out-patient department, out-patient unit).